Increasing evidence indicates that success of targeted therapies in the treatment of cancer is
context-dependent and is influenced by a complex crosstalk between signaling pathways …

Simple Summary Bladder cancer (BC) is a common cancer that causes high morbidity and
mortality among affected patients. As a carcinogen-driven cancer, molecular oncology of BC …

Purpose: Erdafitinib is the only FDA-approved targeted therapy for FGFR2/3-altered
metastatic urothelial cancer. We characterized the genetic landscape of FGFR-altered …

Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy is
recommended for patients with muscle-invasive bladder cancer (MIBC). It has been shown …

Objectives To determine the association between the FGFR3 mutation status and immuno-
histochemistry (IHC) markers (p53 and Ki-67) in invasive bladder cancer (BC), and to …

FGFR3 alterations are common in patients with bladder cancer. While the FGFR tyrosine
kinase inhibitor erdafitinib has been approved as a targeted therapy for patients with FGFR3 …

Background Immune checkpoint blockade (ICB) therapy holds promise in metastatic
urothelial carcinoma (UC). Fibroblast growth factor receptor 3 (FGFR3) mutation drives T-cell …

Backgrounds Despite the genomic landscape of urothelial carcinomas (UC) patients,
especially those with UC of bladder (UCB), has been comprehensively delineated and …

Identification of reliable molecular biomarkers that can complement clinical practice
represents a fascinating challenge in any cancer field. Urothelial carcinoma is a very …

Fibroblast growth factor receptor (FGFR) genomic alterations (GAs) represent an actionable
target, key to the pathogenesis of some urothelial cancers (UCs). Though FGFR GAs are …